-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, U7fYcvyGheKe/aRX6y4gF7qKL1K+cl95nvhn5OovG0E5UBBTtaJn7d7Av0owCfLz NoNkKYB6VQFbRWhVnH5Axg== 0000105770-06-000048.txt : 20060119 0000105770-06-000048.hdr.sgml : 20060119 20060119152233 ACCESSION NUMBER: 0000105770-06-000048 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060113 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20060119 DATE AS OF CHANGE: 20060119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WEST PHARMACEUTICAL SERVICES INC CENTRAL INDEX KEY: 0000105770 STANDARD INDUSTRIAL CLASSIFICATION: FABRICATED RUBBER PRODUCTS, NEC [3060] IRS NUMBER: 231210010 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-08036 FILM NUMBER: 06538064 BUSINESS ADDRESS: STREET 1: 101 GORDON DR STREET 2: P O BOX 645 CITY: LIONVILLE STATE: PA ZIP: 19341-0645 BUSINESS PHONE: 6105942900 MAIL ADDRESS: STREET 1: 101 GORDON DRIVE STREET 2: PO BOX 645 CITY: LIONVILLE STATE: PA ZIP: 19341-0645 FORMER COMPANY: FORMER CONFORMED NAME: WEST CO INC DATE OF NAME CHANGE: 19990405 8-K 1 file8k.htm FILE 8K BECTIN DICKN

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

________________

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported) – January 13, 2006

 

________________________

 

WEST PHARMACEUTICAL SERVICES, INC.

 

(Exact name of registrant as specified in its charter)

 

_____________________

 

 

 

 

 

Pennsylvania

1-8036

23-1210010

(State or other jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

101 Gordon Drive, PO Box 645, Lionville, PA

 

19341-0645

(Address of principal executive offices)

 

(Zip Code)

 

 

(610) 594-2900

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or address, if changed since last report)

____________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

Item 1.01

Entry into a Material Definitive Agreement.

 

On January 13, 2006, West Pharmaceutical Services, Inc. (“West”) entered into a supply contract (the “Supply Agreement”) with Becton, Dickinson and Company (“BD”). BD™ (1) is West’s largest customer, accounting for approximately 11% of West's 2004 consolidated net sales. The Supply Agreement replaces a similar three-year agreement that was entered into in 2001 and is made effective as of October 1, 2004. The Supply Agreement will continue until September 30, 2007.

The Supply Agreement covers all of West’s products currently being sold to BD, including Hemogard™ (1) stoppers for use in BD’s blood-collection systems, elastomer components for BD’s prefilled syringes and plungers for BD’s disposable syringes, all made from West’s formulations in a variety of colors, sizes and configurations. Under the Supply Agreement, BD has agreed to purchase 100% of its requirements for certain Hemogard stoppers and minimum annual quantities of certain other sizes.

The Supply Agreement contains fixed pricing, with discounts and rebates on certain products based on volume and pricing levels. In addition, the Supply Agreement contains a mechanism for adjusting pricing annually based on changes in the synthetic elastomer U.S. Producer Price Index.

 

 

(1) BD and Hemogard are trademarks of Becton, Dickinson and Company.

 

                

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

WEST PHARMACEUTICAL SERVICES, INC.

 

/s/ John R. Gailey III

John R. Gailey III

Vice President, General Counsel and Secretary

 

January 19, 2006

 

 

 

 

 

 -----END PRIVACY-ENHANCED MESSAGE-----